RT @RetinalPhys: Dr. Ciulla describes a study of real-world outcomes from anti-VEGF for ME in RVO done with data from a large database of a… Source by Thomas Ciulla, MD, MBA Return to main website.
RT @ThomasCiullaMD: Pleased by the FDA’s acceptance of our IND for CLS-AX (axitinib injectable suspension), enabling initiation of a Phase… Source by Thomas Ciulla, MD, MBA Return to main website.
Our #ARVO presentation was featured in @OphthTimes Correlation of Best Corrected Visual Acuity and Central Subfield Thickness in #Macular Edema Due to #Retinal Vein Occlusion, #Diabetic Retinopathy and #Uveitis https://t.co/sQi7ts4dEF
Source by Thomas Ciulla, MD, MBA
Interviewed for this recent piece on #Diabetic Macular Edema, a leading cause of #vision loss. More effective & longer acting #treatment is needed: Macular Edema Treatments Less Effective in the Real World https://t.co/dznSe1SpYI via @medscape Source by Thomas Ciulla, MD, MBA Return to main website.
Pleased by the FDA’s acceptance of our IND for CLS-AX (axitinib injectable suspension), enabling initiation of a Phase 1/2a clinical trial in neovascular AMD by the end of 2020! Our related recently-published ARVO abstract: https://t.co/tR0Wd8yueY #retina #biotech #medicine https://t.co/WiTT8ziDgs Source by Thomas Ciulla, MD, MBA …
RT @ThomasCiullaMD: Recently published…Diabetic macular edema, a leading cause of vision loss, is treated less intensely and shows worse…
Source by Thomas Ciulla, MD, MBA